Sign In
Buy FBLG
$1.07
+0.0200 (+1.90%)
At Close: Jun 03, 2026
FibroBiologics to Present at the 2025 ThinkEquity Conference
08:30am, Tuesday, 14'th Oct 2025
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
08:30am, Tuesday, 23'rd Sep 2025
HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:30am, Wednesday, 27'th Aug 2025
HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:30pm, Thursday, 31'st Jul 2025
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
08:30am, Monday, 28'th Jul 2025
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics to Present at the Advanced Wound Care Summit USA
08:30am, Friday, 11'th Jul 2025
HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics, Inc. announced an advancement in its cartilage repair program. FibroBiologics has confirmed, through both immunohistochemistry and transcriptomic analysis, that the CYWC628 spheroids u
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
04:35pm, Monday, 07'th Jul 2025
HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
04:35pm, Monday, 16'th Jun 2025
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics to Present at the BIO International Convention 2025
09:50am, Monday, 16'th Jun 2025
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
08:30am, Monday, 09'th Jun 2025
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth Seasoned finance executive brings over 20 years of public company and
